Abstract
Iron oxide (IO) nanoparticles hold great promise as diagnostic and therapeutic agents in oncology. Their intrinsic physical properties make IO nanoparticles particularly interesting for simultaneous drug delivery, molecular imaging, and applications such as localized hyperthermia. Multiple non-targeted IO nanoparticle preparations have entered clinical trials, but more exciting, new tumortargeted IO nanoparticle preparations are currently being tested in preclinical settings. This paper will analyze the challenges faced by this new theranostic modality, with a specific focus on the interactions of IO nanoparticles with the innate and adaptive immune systems, and their effect on nanoparticle biodistribution and tumor targeting. Next, we will review the critical need for innovative surface chemistry solutions and strategies to overcome the immune interactions that prevent existing tumor-targeted IO preparations from entering clinical trials. Finally, we will provide an outlook for the future role of IO nanoparticles in oncology, which have the promise of becoming significant contributors to improved diagnosis and treatment of cancer patients.
Keywords: Iron oxide nanoparticles, tumor targeting, immunology, inflammation, macrophage, nanoparticle surface chemistry, cancer theranostics.
Current Pharmaceutical Design
Title:Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology
Volume: 19 Issue: 37
Author(s): Dana C. Baiu, Christopher S. Brazel, Yuping Bao and Mario Otto
Affiliation:
Keywords: Iron oxide nanoparticles, tumor targeting, immunology, inflammation, macrophage, nanoparticle surface chemistry, cancer theranostics.
Abstract: Iron oxide (IO) nanoparticles hold great promise as diagnostic and therapeutic agents in oncology. Their intrinsic physical properties make IO nanoparticles particularly interesting for simultaneous drug delivery, molecular imaging, and applications such as localized hyperthermia. Multiple non-targeted IO nanoparticle preparations have entered clinical trials, but more exciting, new tumortargeted IO nanoparticle preparations are currently being tested in preclinical settings. This paper will analyze the challenges faced by this new theranostic modality, with a specific focus on the interactions of IO nanoparticles with the innate and adaptive immune systems, and their effect on nanoparticle biodistribution and tumor targeting. Next, we will review the critical need for innovative surface chemistry solutions and strategies to overcome the immune interactions that prevent existing tumor-targeted IO preparations from entering clinical trials. Finally, we will provide an outlook for the future role of IO nanoparticles in oncology, which have the promise of becoming significant contributors to improved diagnosis and treatment of cancer patients.
Export Options
About this article
Cite this article as:
C. Baiu Dana, S. Brazel Christopher, Bao Yuping and Otto Mario, Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology, Current Pharmaceutical Design 2013; 19 (37) . https://dx.doi.org/10.2174/13816128113199990409
DOI https://dx.doi.org/10.2174/13816128113199990409 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG
Current Vascular Pharmacology The Clinical Usefulness of Nuclear Medicine Techniques in the Diagnosis of Vascular Graft Infections
Current Molecular Imaging (Discontinued) Knockdown of C-C Chemokine Receptor 5 (CCR5) is Protective Against Cerebral Ischemia and Reperfusion Injury
Current Neurovascular Research Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies
Current Vascular Pharmacology Pattern of Primary Vasculitis with Peripheral Ischemic Manifestations: Report of a Case Series and Role of Vascular Surgery
Current Rheumatology Reviews Injectable <i>In-Situ</i> Forming Depot of Doxycycline Hyclate/α-Cyclodextrin Complex Using PLGA for Periodontitis Treatment: Preparation, Characterization, and <i>In-Vitro</i> Evaluation
Current Drug Delivery Whole Milk and Full-Fat Dairy Products and Hypertensive Risks
Current Hypertension Reviews Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Stent Thrombosis and Duration of Dual Antiplatelet Therapy
Current Pharmaceutical Design Inflammation-Induced Thrombosis: Mechanisms, Disease Associations and Management
Current Pharmaceutical Design IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine
Current Pharmaceutical Design Role of the LDL Receptor-Related Protein 1 in Regulating Protease Activity and Signaling Pathways in the Vasculature
Current Drug Targets Silent Partner in Blood Vessel Homeostasis? Pervasive Role of Nitric Oxide in Vascular Disease
Current Hypertension Reviews Application of Transcranial Color-Coded Duplex Sonography in Stroke Diagnosis
Current Medical Imaging Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Adipose Tissue and Bone Marrow as Sources for Cell-based Therapeutic Angiogenesis in Ischemic Tissues: Biological Foundation and Clinical Prospects for Age-related Vascular Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Demystifying the ACE Polymorphism: From Genetics to Biology
Current Pharmaceutical Design Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Pharmacological Inhibition of Poly(ADP-ribose) Polymerase in Cardiovascular Disorders: Future Directions
Current Vascular Pharmacology Novel Concept in the Mechanism of Injury and Protection of Gastric Mucosa: Role of Renin-Angiotensin System and Active Metabolites of Angiotensin
Current Medicinal Chemistry